UNICYCIVE THERAPEUTICS, INC. Net Change in Cash
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Net Change in Cash of $18.36 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-08-14
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $23.88M.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$2.96M, a 2112.93% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $147.00K.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$16.12M, a 197.26% decline from fiscal 2021.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $16.58M.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$15.00K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-06-30 | $18.36M 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $23.88M 10-Q · filed 2023-05-16 | |||
| 2022-12-31 | -$16.12M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$9.57M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$6.01M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$2.96M 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | $16.58M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $18.01M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $147.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$15.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $48.00K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$14.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |